Carlsmed, Inc. (CARL) Stock Price & Analysis
Carlsmed, Inc. (CARL) rose 2.17% to USD 11.29 as of June 10, 2026 at 04:57 UTC, according to Nexqual real-time market data.
CARL last closed at USD 11.05; the session ranged USD 10.81–11.45 on volume of 73,498 shares. Market capitalization is $306.92M, with a 52-week range of USD 8.5–17.19 (NMS). Source: Nexqual, June 10, 2026 at 04:57 UTC.
Key Statistics (as of June 10, 2026 at 04:57 UTC)
| Price | USD 11.29 |
|---|---|
| Change | ▲ 2.17% (up) |
| Previous Close | USD 11.05 |
| Open | USD 11.17 |
| Day Range | USD 10.81 – 11.45 |
| 52-Week Range | USD 8.5 – 17.19 |
| Volume | 73,498 shares |
| Market Cap | $306.92M |
| Exchange | NMS |
Technical Analysis (CARL)
Nexqual's technical model rates CARL "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 04:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.08 (neutral) |
| vs SMA50 | Above (USD 10.32) |
| MACD | 0.17 (positive) |
Analyst Ratings (CARL)
Wall Street analysts rate CARL "Strong Buy" based on 5 analysts, with a mean price target of USD 18.4 (range USD 16–23), per Nexqual as of June 10, 2026 at 04:57 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 18.4 |
| High Target | USD 23 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (CARL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $18.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.26 vs est -0.4 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.43 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.49 ▲ beat |
| 2025-06-30 | USD -1.37 vs est -0.92 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
Financials & Fundamentals (CARL)
| Total Revenue | $56.44M |
|---|---|
| Revenue Growth (YoY) | +58.20% |
| Gross Margin | +75.89% |
| Operating Margin | -57.56% |
| Profit Margin | -57.76% |
| ROE | -52.43% |
| Debt / Equity | 18.71 |
| Current Ratio | 11.88 |
| Total Cash | $97.02M |
| Total Debt | $17.25M |
| Free Cash Flow | $-26.40M |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
Financial Health Score (CARL)
Nexqual rates Carlsmed, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:57 UTC.
| Growth | Strong — Revenue +58% YoY (latest Q) |
|---|---|
| Profitability | Solid — Gross margin 76%, operating -58% |
| Balance Sheet | Strong — $97M cash vs $17M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$26M, burning cash |
| Efficiency | Critical — ROE -52%, ROA -24.2% |
Ownership (CARL)
| Insider Ownership | +43.53% |
|---|---|
| Institutional Ownership | +39.74% |
| Shares Outstanding | 27.18M |
| Float | 9.91M |
| Short % of Float | +12.93% |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
Leadership (CARL)
Carlsmed, Inc. is led by Michael John Cordonnier (age 48), Co-Founder, Chairman, CEO & President, per Nexqual as of June 10, 2026 at 04:57 UTC.
| Co-Founder, Chairman, CEO & President | Michael John Cordonnier (age 48) |
|---|---|
| Co-Founder, Chief Intellectual Property Officer & Director | Niall Patrick Casey (age 48) |
| CFO & Treasurer | Leonard M. Greenstein (age 49) |
| Chief Technology Officer | Shariq Hussain |
| Senior Vice President of People & Culture | Jodi Allen Coe |
Major Backers & Investors (CARL)
Notable institutional backers of Carlsmed, Inc. include Orbimed Advisors LLC., Janus Henderson Group PLC, JANUS INVESTMENT FUND-Janus Henderson Venture Fund, according to Nexqual as of June 10, 2026 at 04:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 4.61% |
| Janus Henderson Group PLC | 4.52% |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 3.63% |
| Parkman Healthcare Partners LLC | 1.92% |
| Schonfeld Strategic Advisors Llc | 1.04% |
| KCM Capital Inc | 0.74% |
| Russell Investments Group, Ltd. | 0.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.41% |
| Vanguard Group | 2.01% |
| Geode Capital | 0.71% |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
From Carlsmed, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.
- The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
- Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HTFL | Heartflow, Inc. | USD 28.67 | ▲ 2.03% |
| KMTS | Kestra Medical Technologies, Lt | USD 19.92 | ▲ 2.68% |
| BBNX | Beta Bionics, Inc. | USD 14.39 | ▲ 3.6% |
| CBLL | CeriBell, Inc. | USD 18.5 | ▲ 1.37% |
| NIQ | NIQ Global Intelligence plc | USD 8.32 | ▼ 0.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:57 UTC. This page is informational and not investment advice.